UPDATE: JP Morgan Raises GW Pharmaceuticals Tgt To $215 As Firm Believes 'Epidiolex is on track to come in north of $150M in its first full year (with off label use being a major potential swing factor)' Easily Exceeding Firm's Initial Expectations